Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/182735
Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Post-transplant diabetes mellitus (PTDM) is a common problem after kidney transplantation (KT), occurring in 50% of high-risk recipients. The clinical importance of PTDM lies in its impactas a significant risk factor for cardiovascular and chronic kidney disease (CKD) after solid organ transplantation. Kidney Disease: Improving Global Outcomes (KDIGO) has recently updated the treatment guidelines for diabetes management in CKD with emphasis on the newer antidiabetic agents such as dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter 2 inhibitors as add-on therapy to metformin. Given all these new diabetes treatments and the updated KDIGO guidelines, it is necessary to evaluate and give guidance on their use for DM management in KT recipients. This review summarizes the scarce published literature about the use of these new agents in the KT field. In summary, it is absolutely necessary to generate evidence in order to be able to safely use these new treatments in the KT population to improve blood glucose control, but specially to evaluate their potential cardiovascular and renal benefits that would seem to be independent of blood glucose control in PTDM patients.
Subject
Subject (English)
Citation
Citation
MONTERO, Nuria, et al. Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics. Clinical Kidney Journal. 2021. Vol. vol 15, num. num 1, pags. 5-13. ISSN 2048-8513. [consulted: 6 of June of 2026]. Available at: https://hdl.handle.net/2445/182735